Curanex Pharmaceuticals Inc
$0.48
▼
-3.9%
2026-04-21 06:18:01
www.curanexpharma.com
NCM: CURX
Explore Curanex Pharmaceuticals Inc stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$12.79 M
Current Price
$0.48
52W High / Low
$9.18 / $0.26
Stock P/E
—
Book Value
$0.01
Dividend Yield
—
ROCE
-37.04%
ROE
-85.25%
Face Value
—
EPS
$-0.02
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
—
Debt / Equity
155.99
Current Ratio
9.37
Quick Ratio
81.93
Forward P/E
—
Price / Sales
—
Enterprise Value
$19.13 M
EV / EBITDA
—
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Aligos Therapeutics, Inc. | $6.51 | — | $41.33 M | — | -130.74% | -1.97% | $13.69 / $4.2 | $8.67 |
| 2. | Vaxcyte, Inc. | $61.4 | — | $8.86 B | — | -33.02% | -25.59% | $65 / $28.09 | $20.49 |
| 3. | Kairos Pharma, Ltd. | $0.63 | — | $13.1 M | — | -87.87% | -97.99% | $2.11 / $0.4 | $0.37 |
| 4. | INmune Bio Inc. | $1.49 | — | $39.61 M | — | -128.97% | -1.65% | $11.64 / $1.09 | $0.89 |
| 5. | Pluri Inc. | $3.59 | — | $36.08 M | — | -348.95% | 669.52% | $7.13 / $2.82 | $-1.46 |
| 6. | Polyrizon Ltd. | $11.64 | — | $20.34 M | — | -27.56% | -25.38% | $2,235 / $2.88 | $13.05 |
| 7. | BioMarin Pharmaceutical Inc. | $54.33 | 30.1 | $10.47 B | — | 5.99% | 5.94% | $66.28 / $50.76 | $31.65 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -3.09 M | -0.95 M | -0.06 M | -0.14 M | -0.06 M | — |
| Net Profit | -3.07 M | -0.95 M | -0.06 M | -0.14 M | -0.14 M | — |
| EPS in Rs | -0.11 | -0.03 | -0 | -0 | -0 | -0 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0.03 M |
| Operating Profit | -4.24 M | -0.29 M | -0.02 M | -0.02 M |
| Net Profit | -4.23 M | -0.36 M | -0.02 M | -0.02 M |
| EPS in Rs | -0.15 | -0.01 | -0 | -0 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 11.58 M | 0.52 M | 0.07 M | 0.01 M |
| Total Liabilities | 0.36 M | 0.01 M | 0.01 M | 0 M |
| Equity | 11.22 M | 0.5 M | 0.06 M | 0.01 M |
| Current Assets | 11.23 M | 0.52 M | 0.07 M | 0.01 M |
| Current Liabilities | 0.14 M | 0.01 M | 0.01 M | 0 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -10.48 M | -0.56 M | -0 M | 0 M |
| Investing CF | — | — | — | — |
| Financing CF | 15.31 M | 0.63 M | 0.07 M | -0 M |
| Free CF | -10.48 M | -0.56 M | -0 M | 0 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | -100% | — |
| Earnings Growth % | -1068.75% | -1783.04% | 5.12% | — |
| Profit Margin % | — | — | — | -77.82% |
| Operating Margin % | — | — | — | -77.82% |
| Gross Margin % | — | — | — | 17.03% |
| EBITDA Margin % | — | — | — | 3.56% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.